NASDAQ:CGON CG Oncology Q3 2025 Earnings Report $42.85 -0.11 (-0.26%) Closing price 04:00 PM EasternExtended Trading$42.34 -0.52 (-1.20%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast CG Oncology EPS ResultsActual EPSN/AConsensus EPS -$0.57Beat/MissN/AOne Year Ago EPSN/ACG Oncology Revenue ResultsActual RevenueN/AExpected Revenue$0.07 millionBeat/MissN/AYoY Revenue GrowthN/ACG Oncology Announcement DetailsQuarterQ3 2025Date11/11/2025TimeBefore Market OpensConference Call DateWednesday, November 12, 2025Conference Call Time12:30PM ETConference Call ResourcesEarnings HistoryCompany Profile CG Oncology Earnings HeadlinesCG Oncology (CGON): Assessing Valuation Following Analyst Coverage and Positive Phase 3 Trial ResultsOctober 10, 2025 | finance.yahoo.comCG Oncology: Upgraded, Rising, But Should We Still Be Optimistic?October 9, 2025 | seekingalpha.comForget AI, This New Tech Trend Could Be BiggerQuantum computing could be the biggest revolution since fire — and Bank of America says it’s about to reshape everything from AI to clean energy. I’ve pinpointed three stocks best positioned for this “Quantum Flashpoint,” and I’ll reveal them live this Tuesday at 8 p.m. ET.October 14 at 2:00 AM | Brownstone Research (Ad)Guggenheim Initiates Coverage of CG Oncology (CGON) with Buy RecommendationOctober 9, 2025 | msn.comCG Oncology jumps as Guggenheim starts at Buy on potential against bladder cancerOctober 9, 2025 | msn.comCG Oncology initiated with a Buy at GuggenheimOctober 8, 2025 | msn.comSee More CG Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CG Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CG Oncology and other key companies, straight to your email. Email Address About CG OncologyCG Oncology (NASDAQ:CGON) (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity. Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates. The company’s discovery engine integrates high-throughput screening, structure-based design and biomarker development, enabling rapid iteration and selection of molecules with favorable pharmacological profiles. Since its founding, CG Oncology has built a management team with extensive experience in oncology drug development, regulatory strategy and commercial planning. The organization continues to expand its pipeline by pursuing additional immuno-oncology targets and exploring strategic collaborations to accelerate the translation of its antibody assets from preclinical research into the clinic. Through these efforts, CG Oncology aims to create differentiated therapies that address unmet needs in the treatment of solid tumor malignancies.View CG Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff Concerns Upcoming Earnings ASML (10/15/2025)Abbott Laboratories (10/15/2025)Bank of America (10/15/2025)Kinder Morgan (10/15/2025)Morgan Stanley (10/15/2025)Progressive (10/15/2025)Prologis (10/15/2025)The PNC Financial Services Group (10/15/2025)CSX (10/16/2025)Interactive Brokers Group (10/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
